Therapeutic Innovations and Resistance (INTHERES), Université de Toulouse INRAE ENVT, Toulouse 31076, France; Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France.
Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France.
Poult Sci. 2024 Nov;103(11):104200. doi: 10.1016/j.psj.2024.104200. Epub 2024 Aug 8.
Sulfonamides (S) are old bacteriostatic antibiotics which are widely prescribed in combination with trimethoprim (TMP) for the treatment of various diseases in food-producing animals such as poultry. Nowadays, the 1:5 dose ratio of TMP/S used in broilers is a direct transposition of the ratio determined in Human decades ago for TMP/sulfamethoxazole (SMX), aiming to obtain a supposed synergistic plasma concentration ratio of 1:19. However, major pharmacokinetics (PK) differences exist according to the sulfonamide used in the combination. Here, we generated new PK data in broilers after a cross-over design with IV and the oral administration of 2 major sulfonamides, sulfadiazine (SDZ) and SMX, in combination with TMP, and analyzed the data via a population pharmacokinetic (popPK) modeling approach. Results showed that TMP has a greater plasma to tissue distribution than both sulfonamides with a higher volume of distribution (0.51 L/kg for SDZ, 0.62 L/kg for SMX and 3.14 L/kg for TMP). SMX has the highest elimination half-life (2.83 h) followed by SDZ and TMP (2.01 h and 1.49 h, respectively). The oral bioavailability of the 3 molecules was approximately 100%. Bodyweight could explain some of the inter-individual variability in the volume of distribution of SDZ and SMX and the clearance of SDZ and TMP, as heavier broilers have higher typical values. Monte Carlo simulations of a large virtual broiler population (n = 1,000) showed that the targeted plasma ratio of TMP:S of 1:19 was rarely or never reached at the individual level for both combinations at the marketed doses and greatly varies over time and between individuals, questioning the relevance of the 1:5 dose ratio for current formulations of TMP/S.
磺胺类药物(S)是一种古老的抑菌抗生素,广泛与甲氧苄啶(TMP)联合用于治疗家禽等食用动物的各种疾病。如今,肉鸡中 TMP/S 采用的 1:5 剂量比是几十年前在人类中确定的 TMP/磺胺甲恶唑(SMX)的直接转置,旨在获得假设的 1:19 协同血浆浓度比。然而,根据组合中使用的磺胺类药物,存在主要的药代动力学(PK)差异。在这里,我们通过 IV 和口服交叉设计在肉鸡中生成了新的 PK 数据,使用 2 种主要的磺胺类药物磺胺嘧啶(SDZ)和 SMX 与 TMP 联合,并通过群体药代动力学(popPK)建模方法分析了数据。结果表明,TMP 与磺胺类药物相比具有更大的血浆向组织分布,具有更高的分布容积(SDZ 为 0.51 L/kg,SMX 为 0.62 L/kg,TMP 为 3.14 L/kg)。SMX 的消除半衰期最长(2.83 h),其次是 SDZ 和 TMP(分别为 2.01 h 和 1.49 h)。3 种分子的口服生物利用度约为 100%。体重可以解释 SDZ 和 SMX 分布容积以及 SDZ 和 TMP 清除率的个体间变异性的一部分,因为较重的肉鸡具有更高的典型值。对大型虚拟肉鸡群体(n=1000)的蒙特卡罗模拟显示,在市场剂量下,两种组合的个体水平很少或从未达到目标 TMP:S 血浆比 1:19,并且在时间和个体之间差异很大,这使得当前 TMP/S 制剂的 1:5 剂量比的相关性受到质疑。